Debevoise Advises Lannett in its $1.23 Billion Acquisition of Kremers Urban Pharmaceuticals

2 September 2015

Debevoise & Plimpton LLP is advising Lannett Company, Inc. (“Lannett”)‎ in its acquisition for $1.23 billion in cash, plus additional contingent consideration, of Kremers Urban Pharmaceuticals Inc., the U.S. specialty generic pharmaceuticals subsidiary of global biopharmaceuticals company UCB S.A. The transaction, subject to regulatory approval and other customary closing conditions, is expected to close in the fourth quarter of calendar 2015.

Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications.

The Debevoise team is led by partner Andrew L. Bab and includes partners Jennifer L. Chu, Gary M. Friedman and Scott B. Selinger, counsel Judith L. Church, Stuart Hammer and Charles E. Wachsstock, and associates Vincent J. Bianco, Patrick Fasoro, Andrew M. Hirsch, David A. Martinez, Kamal Nesfield and Ashwin D. Phadnis.

Debevoise & Plimpton LLP is a premier law firm with market-leading practices, a global perspective and strong New York roots. We deliver effective solutions to our clients’ most important legal challenges, applying clear commercial judgment and a distinctively collaborative approach.